314 resultados para Hitchcock
Resumo:
Contribution from Bureau of Plant Industry.
Resumo:
Mode of access: Internet.
Resumo:
Cover title.
Resumo:
Top Row: Felicia Allen, Michael Anderson, Lisa Armstead, Shannon Arterburn, April Ballard, Stacey Bancroft, Veronica Barcelona, Mary Barringer, Jaralee Basso, Courtney Beck, Karina Bouffard, Becky Bradford, Dawn Burdette, Biance Cerroni
Row 2: Surlin Chadha, James Chambers, Matt Brady, Trish Donovan, Patricia Letowrneau, Amy Prouty, Mary Hawk, Kim Yaekle, Joy Caraan, Jill Awai, Kerry Szymke, Lawra Knapp, Trish Therrian, Kelly Collardey, Julie Collins
Row 3: Kimberly Collins, Jill Collison, Michelle Colvia, Erika Cross, Erin Dassance, Amanda DeFever
Row 4: Janis Dinnel, Corey Eisenberg, Lisa Falzetta, Amy Farley, Jennifer Fulcher, Lori George, Pamela George, Royace A. Gibson
Row 5: Pamela Giles, Nicole Grecu, Janet Green, Jessica Grose, Jill Hall, Jill Hiler, Shamika Hinson, Melissa Hitchcock
Row 6: Rebekah Hopper, Steven Thrke, Kevri Johnson, Rebecca Johnson, Shannon Johnson, Jan Lee, Beverly Jones, Ada Sue Hinshaw, Susan Boehm, Nola Pender, Patricia Coleman Burn, Jody Joslyn, Jennifer Kerr, Erin Kingsley, Heather Knudsen, Kristie Krzyzanski
Row 7: Sarah Kyle, Michelle Laughlis, Julie Leibowitz, Erin Maki, Rachel Malone, Amanda Manoni, Kara marsh, Carrie McClung, Kristi Miller, Kristine Moe, Kimberly Morton, Thecla Moschouris, Meg Mountainbear, Michelle Newberg, Aarti parekh, Heather Pawlak
Row 8: Diana Piergentili, Alison Pinta, Gail Prahaska, Jennifer Pruchnik, Kimberly Rendz, Sarah Repp, Eunice Rhiew, Kyle Rinehart, Roni robarge, Audrey Salazar, Dana Schaffner, Sally Scott, Nicole Sell, Mary Jean Siasoco, Deborah Slizewski, Rebecca Snyder
Row 9: Carmen Taylor, Chereena Tennis, Monigue Tett, Lindsay Thibert, Cindy Thompson, Alpa Tolia, Jessie Ulmer, Shannon Waigle, Jennifer Walsh, MacKenzie Waters, Christie Wiseley, Mari Yelorda
Resumo:
Mode of access: Internet.
Resumo:
Mode of access: Internet.
Resumo:
Final issue consulted.
Resumo:
Description based on: Vol. 1, no. 2 (Jan. 1879); title from cover.
Resumo:
Mode of access: Internet.
Resumo:
To compare the incidence of foetal malformations (FMs) in pregnant women with epilepsy treated with different anti-epileptic drugs (AED) and doses, and the influence of seizures, family and personal history, and environmental factors. A prospective, observational, community-based cohort study. Methods. A voluntary, Australia-wide, telephone-interview-based register prospectively enrolling three groups of pregnant women: taking AEDs for epilepsy; with epilepsy not taking AEDs; taking AEDs for a non-epileptic indication. Four hundred and fifty eligible women were enrolled over 40 months. Three hundred and ninety six pregnancies had been completed, with 7 sets of twins, for a total of 403 pregnancy outcomes. Results. 354 (87.8%) pregnancy outcomes resulted in a healthy live birth, 26 (6.5%) had a FM, 4 (1%) a death in utero, 1 (0.2%) a premature labour with stillbirth, 14 (3.5%) a spontaneous abortion and 4 lost to follow-up. The FM rate was greater in pregnancies exposed to sodium valproate (VPA) in the first trimester (116.0%) compared with those exposed to all other AEDs (16.0% vs. 2.4%, P < 0.01) or no AEDs (16.0% vs. 3.1 %, P < 0.01). The mean daily dose of VPA taken in pregnancy with FMs was significantly greater than in those without (11975 vs: 1128 mg, P < 0.01). The incidence of FM with VPA doses greater than or equal to 1100 mg was 30.2% vs. 3.2% with doses < 1100 mg (P < 0.01). Conclusions. There is a dose-effect relationship for FM and exposure to VPA during the first trimester of pregnancy, with higher doses of VPA associated with a significantly greater risk than with lower doses or with other AEDs. These results highlight the need to limit, where possible, the dose of VPA in pregnancy. (C) 2004 Elsevier Ltd. All rights reserved.
Resumo:
The XPS peaks of Fe 3p for Fe2+ and Fe3+ in FeO and Fe2O3, respectively, have been measured and the effects of curve fitting parameters on interpretation of the data have been analysed. Firstly, the peak fit parameters, i.e. (1) the number of peaks to be deconvoluted, (2) the range of the peak for back ground subtraction, (3) straight line (Li) or the Shirley (Sh) background subtraction method, (4) GL ratio (the ratio of Gaussian and Lorentzian contribution to the peak shape) and (5) asymmetry factor (AS), are manually selected. Secondly, the standard peak fit parameters were systematically investigated. The peak shape was fitted to a Voigt function by changing the peak position, the peak height and the full width at half maximum (FWHM) to minimize the chi(2). The recommended peak positions and peak parameters for Fe2+ and Fe3+ in iron oxides have been determined. (c) 2006 Elsevier B.V. All rights reserved.
Resumo:
The Australian Pregnancy Registry, affiliated European Register of Antiepileptic drugs in Pregnancy (EURAP), recruits informed consenting women with epilepsy on treatment with antiepileptic drugs (AEDs), those untreated, and women on AEDs for other indications. Enrolment is considered prospective if it has occurred before presence or absence of major foetal malformations (FMs) are known, or retrospective, if they had occurred after the birth of infant or detection of major FM. Telephone Interviews are conducted to ascertain pregnancy outcome and collect data about seizures. To date 630 women have been enrolled, with 565 known pregnancy outcomes. Valproate (VPA) above 1100 mg/day was associated with a significantly higher incidence of FMs than other AEDs (P < 0.05). This was independent of other AED use or potentially confounding factors on multivariate analysis (OR = 7.3, P < 0.0001). Lamotrigine (LTG) monotherapy (n = 65), has so far been free of malformations. Although seizure control was not a primary outcome, we noted that more patients on LTG than on VPA required dose adjustments to control seizures. Data indicate an increased risk of FM in women taking VPA in doses > 1100 mg/day compared with other AEDs. The choice of AED for pregnant women with epilepsy requires assessment of balance of risks between teratogenicity and seizure control.